Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2026-05-12 English
News release - English.pdf
Regulatory Filings
2026-05-02 English
Offering document - English.pdf
Regulatory Filings
2026-05-02 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 87% confidence The document is a CFO’s certification (Form 52-109FV2) attesting to review and fair presentation of the issuer’s interim financial report and MD&A for the period ended February 28, 2026. It is not the interim report itself, nor an announcement of its publication, but a required regulatory form under NI 52-109. It does not constitute the full interim/quarterly report (IR) and does not announce or link to the report; instead it is a standalone certification filing. This best fits the fallback “Regulatory Filings” category.
2026-04-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 75% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” under Canadian NI 52-109, signed by the CEO to certify the issuer’s interim financial report and interim MD&A. It is a regulatory certification form rather than the actual interim report or an announcement of report publication. There is no specific category for certification forms, so the correct classification is the general Regulatory Filings (RNS) fallback.
2026-04-24 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 72% confidence The document is titled FORM 52-109FV2 Certification of Interim Filings under Canadian NI 52-109. It is a CFO’s certification that the interim financial report and interim MD&A have been reviewed and fairly present the issuer’s condition. It does not contain the actual interim financial statements or MD&A text (so it is not the Interim/Quarterly Report itself) and is not announcing a report publication, dividend, or management change. It is a regulatory disclosure (a statutory certification) falling into the catch-all Regulatory Filings category.
2026-04-24 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.